Targeting Lipids, Protecting Hearts: Evidence-Based Strategies for Managing Elevated LDL-C and Lp(a) to Reduce ASCVD Risk
CE Information: 0.50 CNE Credit and AAPA Category 1 credit
Available: April 27, 2026 – April 27, 2027
Completion Time: 30 minutes
Specialties
Cardiology, Primary Care
Target Audience
This initiative is designed to address the professional needs of specialty NPs and PAs involved in the care of patients with atherosclerotic cardiovascular disease (ASCVD).
Elevated LDL-C and lipoprotein(a) [Lp(a)] are well-established contributors to atherosclerotic cardiovascular disease (ASCVD). Ongoing advances in lipid research continue to refine approaches to screening, risk assessment, and management. Engaging with the latest 2026 guideline-based strategies offers opportunities to optimize individualized treatment planning and further improve cardiovascular outcomes across patient populations.
After participating in this education, learners will be able to:
Viet Le
DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert
Associate Professor of Research
Preventative Cardiology PA
Intermountain Health
Murray, UT
Kelly Wulff
NP, FNP-C
Instructor
Boston University Chobanian & Avedisian School of Medicine
Department of Cardiology
Boston Medical Center
Boston, MA
John Bostrom, MD
Assistant Professor of Medicine
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center Cardiovascular Medicine
Boston Medical Center
Boston, MA
Nursing Contact Hours: 0.5 of which none are eligible for pharmacology credit.
Jointly provided by Boston University Chobanian & Avedisian School of Medicine and QDcme.
Supported by an education grant from Merck Sharp & Dohme LLC.
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
Speaker Disclosures
Kelly Wulff, FNO-C, has no relevant financial relationships to disclose.
Viet T. Le, DMSc MPAS PA-C FACC FAHA HF-Cert, is a consultant for Amarin, Irhythm, and Novartis. He is on the advisory board for Amgen, Bayer, Esperion, Idorsia, Merck, and Pfizer. His institution receives research grants from AliveCor, and Janssen/J&J.
The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.
Planner Disclosures
Chelsey Goins, PhD has no relevant financial relationships to disclose.
Núria Waddington Negrão, PhD has no relevant financial relationships to disclose.
Accreditor Disclosures
John Bostrom, MD, Boston University Chobanian & Avedisian School of Medicine’s Accreditation Course Advisor, has no relevant financial relationships to disclose.
Michael Burk, BS, Boston University Chobanian & Avedisian School of Medicine’s Senior Program Manager, has no relevant financial relationships to disclose.
Credit Claiming Instructions
CNE and AAPA
To obtain your CNE and AAPA credit for this activity you will be required to complete the pre-test, review the content presentations, and complete the post test and evaluation. Your certificate will be available for download upon completion.
Boston University Chobanian & Avedisian School of Medicine’s Disclaimer
THIS CONTINUING EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Portions of this educational activity were developed with assistance from generative AI tools: Perplexity (GPT‑5.1) and Claude (Anthropic). Content written by clinical experts was edited using these tool(s) during the months of March and April, 2026. The AI outputs were subsequently reviewed, edited, and approved by the education team and faculty prior to publication.
